Iqbal Singh^1,*, Himanshu Agrawal², Vidhi Maurya², Sanjay Gupta², Alpana Raizada³

Canadian Journal of Urology, Vol.32, No.4, pp. 299-308, 2025, DOI:10.32604/cju.2025.064827 - 29 August 2025

Abstract Objectives: Benign prostatic hyperplasia (BPH) is a common benign tumor in men, with an age-related prevalence of multifactorial etiology. The present study aimed to accurately assess and predict the effect of co-existing metabolic syndrome (MtS) upon treatment outcomes of combination medical therapy in select patients of lower urinary tract symptoms (LUTS) due to BPH. Methods: After obtaining informed consent from the patients, 70 eligible patients with LUTS due to BPH with and without MtS were enrolled in this study from September 2022 to January 2024 from the outpatient clinic at the University College of Medical… More >

Joshua Winograd^1,#, Rebecca Kindler^2,#, Cassidy Lleras², Alia Codelia-Anjum³, Naeem Bhojani⁴, Dean Elterman⁵, Michael A. Diefenbach³, Daniel Ufearo², Katharine Kechejian², Siri Drangsholt², Bilal Chughtai^3,*

Canadian Journal of Urology, Vol.32, No.3, pp. 219-227, 2025, DOI:10.32604/cju.2025.064404 - 27 June 2025

Abstract Introduction: Benign prostatic hypertrophy (BPH) is a common condition affecting men later in life, significantly impacting quality of life (QOL). Surgical intervention is often pursued when medical management fails, but patient satisfaction with outcomes varies. Decisional regret can affect perceived success and patient satisfaction post-surgery. This study evaluates the relationship between post-surgical symptoms and decisional regret across BPH procedures. Methods: A prospective, multicenter cohort study included 54 patients undergoing BPH surgery between March 2023 and February 2024. Patients completed the International Prostate Symptom Score-QOL (IPSS-QOL) scale preoperatively and at least three months postoperatively, along with… More >

Yash B. Shah¹, Brian H. Im¹, Aaron R. Hochberg¹, Elliott P. Freudenburg², James Jiang², Bruce M. Gao², Mihir S. Shah¹, Akhil K. Das^2,*

Canadian Journal of Urology, Vol.32, No.1, pp. 15-19, 2025, DOI:10.32604/cju.2025.064708 - 20 March 2025

Abstract Introduction: Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent, endoscopic management option for benign prostatic hyperplasia (BPH). HoLEP offers a distinct advantage for patients who are at high-risk for bleeding whilst preserving prostatic tissue for pathology analysis, unlike photoselective vaporization. Further, HoLEP avoids the need for cystotomy, unlike simple open and robotic prostatectomy, by using intravesical morcellation. We report our experience with the first 1000 HoLEP procedures at our institution. Materials and Methods: We performed a retrospective review of all HoLEP procedures performed at our institution from 2013–2021 to capture patient demographics, procedure details,… More >

Aalya Hamouda¹, Ahmed Ibrahim², Nicholas Corsi³, Giampaolo Siena⁴,Dean S. Elterman⁵, Bilal Chughtai⁶, Naeem Bhojani², Francesco Sessa⁴, Anna Rivetti⁴, Silvia Secco⁷, Kevin C. Zorn^2,8

Canadian Journal of Urology, Vol.31, No.1, pp. 11802-11808, 2024

Abstract Minimally invasive surgery techniques (MIST) have become newly adopted in urological care. Given this, new analgesic techniques are important in optimizing patient outcomes and resource management. Rez ūm treatment (RT) for BPH has emerged as a new MIST with excellent patient outcomes, including improving quality of life (QoL) and International Prostate Symptom Scores (IPSSs), while also preserving sexual function. Currently, the standard analgesic approach for RT involves a peri prostatic nerve block (PNB) using a transrectal ultrasound (TRUS) or systemic sedation anesthesia. The TRUS approach is invasive, uncomfortable, and holds a risk of infection. Additionally,… More >

Bruce M. Gao, Seyedamirvala Saadat, Edward J. H. Choi, James Jiang, Akhil K. Das

Canadian Journal of Urology, Vol.31, No.3, pp. 11904-11907, 2024

Abstract Holmium enucleation of the prostate (HoLEP) is a gold standard, size-independent surgical treatment for benign prostatic hyperplasia (BPH) distinguished for its efficacy in tissue removal, shorter catheterization durations, lower transfusion rates, and decreased hospital stays when compared to transurethral resection of the prostate (TURP). The objective of this article is to demonstrate the step-by-step procedure of holmium laser cystolitholapaxy and enucleation of the prostate for BPH, emphasizing a top-down modified two-lobe technique with early apical release which enhances visualization and irrigation flow during the enucleation process. More >

Joshua Winograd^1,*, John Lama^1,*, Alia Codelia-Anjum², Naeem Bhojani³, Dean S. Elterman⁴, Kevin C. Zorn^3,5, Eric Margolis⁶, Jamin Brahmbhatt⁷, Ricardo Gonzalez⁸, Bilal Chughtai²

Canadian Journal of Urology, Vol.31, No.6, pp. 12053-12059, 2024

Abstract Introduction: Benign prostatic hyperplasia (BPH) is a prevalent condition affecting a significant portion of the male population, leading to secondary lower urinary tract symptoms (LUTS). Alternative therapies such as phytotherapy using Lipidosterolic extract of Serenoa repens (LSESR USPlus) are commonly used. However, the efficacy of LSESr remains controversial due to conflicting data. We sought to determine the effect of a standardized USP-verified Saw Palmetto extract on male LUTS secondary to BPH.
Materials and methods: In this prospective single arm trial, we investigated the efficacy of a standardized USP-verified Saw Palmetto extract in treating male LUTS secondary to More >

Alexis E. Te¹, Christina Sze¹, Steven A. Kaplan², Bilal Chughtai¹

Canadian Journal of Urology, Vol.30, No.1, pp. 11408-11413, 2023

Abstract Introduction: A common indication for benign prostate hyperplasia (BPH) therapies is failure to improve with medical therapy. However, pivotal Federal Drug Administration (FDA) registered randomized clinical trials (RCTs) for minimally invasive surgical therapies (MISTs) are designed to be compared to either sham or placebo while off medical therapy at baseline, and as an alternative to medical therapy. There are few if any RCTs reporting the MISTS efficacy in patients with true medical therapy failure. We report on the efficacy of robotic water jet ablation therapy (RWT) and TURP in patients who have failed to improve with… More >

Matt S. Ashley¹, Jason Phillips², Gregg Eure³

Canadian Journal of Urology, Vol.30, No.2, pp. 11509-11515, 2023

Abstract Millions of men in North America suffering from lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) are managed on medical therapy. Most patients, however, report poor adherence, and yet relatively few pursue more definitive surgical solutions. The Prostatic Urethral Lift (PUL) was designed to address many of the patient-identified barriers to surgery, namely iatrogenic sexual dysfunction, incontinence, lengthy recovery and postoperative catheterization. Randomized studies and large real world multicenter and database studies have demonstrated safety and effectiveness of PUL when addressing lateral lobe disease. In recent years further technique and device development… More >

Tawfik Elsherbini^1,*, David Bouhadana^2,*, Iman Sadri³, David-Dan Nguyen⁴, Kyle W. Law⁵, Adel Arezki³, Claudia Deyirmendjian¹, Ahmed Ibrahim⁵, Naeem Bhojani⁵, Dean S. Elterman⁶, Bilal Chughtai⁷, Franck Bruyère⁸, Luca Cindolo⁹, Giovanni Ferrari⁹, Carlos Vasquez-Lastra¹⁰, Tiago Borelli-Bovo¹¹, Edgardo F. Becher¹², Hannes Cash¹³, Maximillian Reimann¹⁴, Enrique Rijo¹⁵, Vincent Misrai¹⁶, Kevin C. Zorn⁵

Canadian Journal of Urology, Vol.30, No.2, pp. 11473-11479, 2023

Abstract Introduction: In this study, we sought to investigate the impact of 5-alpha reductase inhibitors (5-ARI) on the perioperative and functional outcomes of 180-Watt XPS GreenLight photovaporization of the prostate (PVP) using a large international database.
Materials and methods: Data were obtained from the Global GreenLight Group (GGG) database, which includes eight high-volume, experienced surgeons from seven international centers. All men with established benign prostatic hyperplasia (BPH) with known 5-ARI status who underwent GreenLight PVP using the XPS-180W system between 2011 and 2019 were eligible for the study. Patients were assigned to two groups based on the preoperative… More >

Dean S. Elterman¹, Bruce Gao¹, Kevin C. Zorn², Naeem Bhojani², Alexis Te³, Bilal Chughtai³, Steven A. Kaplan

Canadian Journal of Urology, Vol.30, No.3, pp. 11568-11573, 2023

Abstract Benign prostatic hyperplasia (BPH) is a common and progressive disease affecting aging men which has a significant impact on quality of life. The Optilume BPH Catheter System (Optilume BPH) is a prostatic dilation system that combines balloon dilation with a localized transfer of paclitaxel to maintain long term patency. Optilume BPH can be deployed using standard rigid cystoscopy without general anesthesia in an office setting. Prospective data indicate that Optilume BPH has favorable functional and sexual patient outcomes. Readers will familiarize themselves with Optilume BPH, significant historical studies and the technique for deploying Optilume BPH. More >